7T metabolic MRI in glioma & epilepsy

Recruiting

• Conditions: brain cancer; epilepsy:convulsion disorder; glioma: brain tumor; seizure disorder; 10029211; 10039911

• Registration Number: NL-OMON55209
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 50

Inclusion Criteria

• Aged 16 years or over and able to exercise their free will (capacitated);
• Diagnosed with glioma-associated epilepsy or focal epilepsy with a relevant
lesion on conventional MRI or PET;
• Scheduled for surgical treatment;
• Informed and having given informed consent

Exclusion Criteria

• The presence of claustrophobia;
• MRI-specific exclusion criteria, such as metallic implants and pregnancy;
• Refusal or inability to provide informed consent.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Metabolic imaging measures of different molecules of interest in glioma tissue<br /><br>(including but not limited to: N-acetylaspartate (NAA), choline, creatine, 2HG<br /><br>and cystathionine) and epileptogenic tissue (including but not limited to<br /><br>glutamate, gamma-aminobutyric acid (GABA) and iron) as acquired with 7T<br /><br>metabolic MRI. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Comparison of the metabolic imaging measures of different molecules of interest<br /><br>with histopathological measures.</p><br>